{"indexed":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T20:03:30Z","timestamp":1574453010021},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"URL":"http:\/\/www.springer.com\/tdm","start":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T00:00:00Z","timestamp":1248912000000},"delay-in-days":0,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s00520-009-0704-5","type":"article-journal","created":{"date-parts":[[2009,7,29]],"date-time":"2009-07-29T06:12:22Z","timestamp":1248847942000},"page":"1329-1330","source":"Crossref","is-referenced-by-count":6,"title":"Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid","prefix":"10.1007","volume":"17","author":[{"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,7,30]]},"reference":[{"key":"704_CR1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00520-009-0591-9","volume":"17","author":"M Sayin","year":"2009","unstructured":"Sayin M, Yazici G (2009) Hyperparathyroidism secondary to zoledronic acid infusion: case report. Support Care Cancer 17:469\u2013470","journal-title":"Support Care Cancer"},{"key":"704_CR2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00774-008-0852-6","volume":"26","author":"A Avramidis","year":"2008","unstructured":"Avramidis A, Polyzos SA, Moralidis E et al (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J Bone Miner Metab 26:635\u2013641","journal-title":"J Bone Miner Metab"},{"key":"704_CR3","unstructured":"Polyzos SA, Anastasilakis AD, Efstathiadou Z et al (2009) The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget's disease of bone. Horm Metab Res 4. doi: 10.1016\/j.bone.2009.03.520","DOI":"10.1016\/j.bone.2009.03.520","doi-asserted-by":"crossref"},{"key":"704_CR4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bone.2006.04.032","volume":"39","author":"HE Whitson","year":"2006","unstructured":"Whitson HE, Lobaugh B, Lyles KW (2006) Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone 39:954\u2013958","journal-title":"Bone"},{"key":"704_CR5","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1359\/jbmr.2003.18.5.868","volume":"18","author":"SC Cremers","year":"2003","unstructured":"Cremers SC, Eekhoff ME, Den HJ, Hamdy NA, Vermeij P, Papapoulos SE (2003) Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res 18:868\u2013875","journal-title":"J Bone Miner Res"},{"key":"704_CR6","unstructured":"Polyzos SA, Anastasilakis AD, Terpos E (2009) Paget's disease of bone: a review with emphasis to treatment with zoledronic acid. Expert Rev Endocrinol Metab 4 (in press)","DOI":"10.1586\/eem.09.35","doi-asserted-by":"crossref"},{"key":"704_CR7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.joms.2009.01.012","volume":"67","author":"B Mehrotra","year":"2009","unstructured":"Mehrotra B (2009) Bisphosphonates\u2014role in cancer therapies. J Oral Maxillofac Surg 67:19\u201326","journal-title":"J Oral Maxillofac Surg"},{"key":"704_CR8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V99.2.634","volume":"99","author":"K Nosaka","year":"2002","unstructured":"Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M (2002) Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 99:634\u2013640","journal-title":"Blood"},{"key":"704_CR9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/14728220903025770","volume":"13","author":"M Gavriatopoulou","year":"2009","unstructured":"Gavriatopoulou M, Dimopoulos MA, Christoulas D et al (2009) Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 13:839\u2013848","journal-title":"Expert Opin Ther Targets"},{"key":"704_CR10","first-page":"1383","volume":"82","author":"JF Seymour","year":"1993","unstructured":"Seymour JF, Gagel RF (1993) Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82:1383\u20131394","journal-title":"Blood"}],"container-title":"Supportive Care in Cancer","original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0704-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0704-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0704-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:01:54Z","timestamp":1559095314000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,30]]},"references-count":10,"journal-issue":{"published-print":{"date-parts":[[2009,10]]},"issue":"10"},"alternative-id":["704"],"URL":"http:\/\/dx.doi.org\/10.1007\/s00520-009-0704-5","relation":{"cites":[]},"ISSN":["0941-4355","1433-7339"],"subject":["Oncology"],"container-title-short":"Support Care Cancer"}